Picture of Pell Bio Med Technology Co logo

6949 Pell Bio Med Technology Co Share Price

0.000.00%
tw flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+130.92%
3mn/a
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MA+64.18%
200d MA+64.18%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-30.95%
Return on Equity-40.46%
Operating Margin-2280.52%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Pell Bio Med Technology Co EPS forecast chart

Profile Summary

Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    December 31st, 2023
    Incorporated
    March 30th, 2017
    Public Since
    March 8th, 2024
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    tw flag iconTaiwan Stock Exchange
    Shares in Issue
    57,117,550
    Blurred out image of a map
    Address
    4F, TAIPEI, 114
    Web
    https://www.pellbmt.com/
    Phone
    +886 287911789
    Auditors
    PricewaterhouseCoopers LLP

    6949 Share Price Performance

    Upcoming Events for 6949

    Pell Bio Med Technology Co Ltd Annual Shareholders Meeting

    Similar to 6949

    Picture of Abnova Taiwan logo

    Abnova Taiwan

    tw flag iconTaiwan Stock Exchange

    Picture of Applied BioCode logo

    Applied BioCode

    tw flag iconTaiwan Stock Exchange

    Picture of Energenesis Biomedical Co logo

    Energenesis Biomedical Co

    tw flag iconTaiwan Stock Exchange

    Picture of Kim Forest Enterprise Co logo

    Kim Forest Enterprise Co

    tw flag iconTaiwan Stock Exchange

    Picture of PHARMAESSENTIA logo

    PHARMAESSENTIA

    tw flag iconTaiwan Stock Exchange

    FAQ